Gold bars to be exempt from tariffs, White House clarifies
Investing.com - Iovance Biotherapeutics (NASDAQ: IOVA) reported second quarter EPS of $-0.33, $0.05 worse than the analyst estimate of $-0.28. Revenue for the quarter came in at $60M versus the consensus estimate of $67.1M.
Guidance
Iovance Biotherapeutics sees FY 2025 revenue of $250.00M-$300.00M versus the analyst consensus of $287.10M.
Iovance Biotherapeutics’s stock price closed at $2.66. It is up 52.00% in the last 3 months and down -66.50% in the last 12 months.
Iovance Biotherapeutics saw 0 positive EPS revisions and 7 negative EPS revisions in the last 90 days. See Iovance Biotherapeutics’s stock price’s past reactions to earnings here.
According to InvestingPro, Iovance Biotherapeutics’s Financial Health score is "fair performance".
Check out Iovance Biotherapeutics’s recent earnings performance, and Iovance Biotherapeutics’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar